EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab

Lakshya Motwani, Vijay Kumar Doddapaneni, Erin L Heuring

Cureus · 23.07.2026

DOI: 10.7759/cureus.113216 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cureus, erschienen am 23.07.2026. Verfasst von Lakshya Motwani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Mercy Health - St. Vincent Medical Center, Toledo, USA. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

immune checkpointimmune checkpoint inhibitor adverse effectsimmune-related adverse event (irae)linear iga bullous dermatosispembrolizumabpembrolizumab cutaneous side effect

Autor:innen und Institutionen

  • Internal Medicine, Mercy Health - St. Vincent Medical Center, Toledo, USA.
  • Dermatology, Mercy Health - St. Vincent Medical Center, Toledo, USA.

Zitieren

APA

Motwani, L., Doddapaneni, V. K., & Heuring, E. L. (2026). Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab. Cureus. https://doi.org/10.7759/cureus.113216

Vancouver

Motwani L, Doddapaneni VK, Heuring EL. Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab. Cureus. 2026. doi:10.7759/cureus.113216

BibTeX
@article{Motwani2026,
  author = {Motwani, Lakshya and Doddapaneni, Vijay Kumar and Heuring, Erin L},
  title = {Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.113216}
}
Kostenlos starten →